NCT07332000Phase 2Recruiting

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Study sponsor: Candel Therapeutics, Inc. · CADL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-02Estimated
Enrollment · participants45Estimated
Source updated2026-09-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Aug 2026. After: Feb 2027.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Biodistribution of aglatimagene besadenovec Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden. After: Measure: Biodistribution of aglatimagene besadenovec.

Planned enrollment increased by 15 participants

Before: 30 participants (planned). After: 45 participants (planned).

Primary completion date changed

Before: Jun 2026. After: Aug 2026.

Check registry source